David Bottomley
Leeds Teaching Hospitals NHS Trust
Quality of lifeInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialHazard ratioExternal beam radiotherapyProstateBrachytherapyProstate brachytherapyProstate cancerDocetaxelImplantNuclear medicineIn patientCastration resistantRadiation therapyIodineMedicine
84Publications
20H-index
4,232Citations
Publications 82
Newest
Source
Source
#1Ruth ConroyH-Index: 3
#2Peter Hoskin (NU: Northwood University)H-Index: 94
Last. James P WylieH-Index: 21
view all 6 authors...
Source
#1Amit BahlH-Index: 12
#2Susan MassonH-Index: 6
Last. Johann S. de BonoH-Index: 124
view all 14 authors...
44 Background: Cabazitaxel, a tubulin-binding taxane, improved survival in mCRPC in the TROPIC trial. Notable toxicities were neutropenia and diarrhoea. We report interim safety and QOL data from a single arm multicentre open label study providing early access to cabazitaxel in the UK. Methods: Patients recruited from 12 centres received cabazitaxel 25mg/m2 intravenously every 3 weeks and prednisolone 10mg daily. Safety assessments were performed before each cycle. Patients completed the EQ-5D q...
12 CitationsSource
#2Paula MandallH-Index: 5
Last. James D. WylieH-Index: 23
view all 6 authors...
192 Background: Treatment with low dose rate brachytherapy (LDR-BT) monotherapy is well established for low risk prostate cancer. The routine use of LDR-BT in intermediate risk (IR) is more controversial and is often combined with additional external beam radiotherapy (EBXRT). We report the biochemical outcome of a large cohort of patients with IR disease treated with LDR-BT monotherapy. Methods: A multi-institutional prospective database identified 615 patients with IR prostate cancer treated w...
Source
#1Ruth ConroyH-Index: 3
#2Peter HoskinH-Index: 94
Last. James D. WylieH-Index: 23
view all 6 authors...
238 Background: We report the outcomes for a cohort of men with higher risk prostate adenocarcinoma treated with LDR brachytherapy in a multi-institutional UK practice. Methods: 217 men treated between 2003-2007 with Iodine-125 brachytherapy at Christie, Leeds and Mount Vernon were identified from a multi-institutional database. Higher risk was defined as patients with ≥ 2 D’Amico intermediate risk factors (PSA 10-20, GS 7 or clinical T2c) or ≥1 high risk factor (PSA > 20, GS ≥ 8). Kaplan-Meier ...
Source
#1Amit BahlH-Index: 24
#2Susan MassonH-Index: 6
Last. J.S. de BonoH-Index: 58
view all 14 authors...
5 CitationsSource
#1C. ParkerH-Index: 8
#1Chris ParkerH-Index: 83
Last. Oliver SartorH-Index: 64
view all 23 authors...
Overall survival benefit and impact on skeletal-related events for radium-223 chloride (Alpharadin) in the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases : A phase III randomized trial (ALSYMPCA)
10 CitationsSource
#1Hima Bindu MusunuruH-Index: 12
#2David BottomleyH-Index: 20
Last. Ann HenryH-Index: 32
view all 8 authors...
Source
#1Nicholas P. Munro (St James's University Hospital)H-Index: 7
#2Bashar Al-Qaisieh (St James's University Hospital)H-Index: 17
Last. Ann Henry (St James's University Hospital)H-Index: 32
view all 8 authors...
Abstract Background and purpose The effect of predominating Gleason grade (3+4 versus 4+3) in Gleason sum score (GS) 7 prostate cancer (PCa) on brachytherapy outcomes is unclear. The 10year experience of permanent brachytherapy monotherapy at a single UK centre for GS 7, intermediate risk (Memorial Sloan-Kettering model), PSA⩽10ng/ml, localised PCa is reported. Materials and methods Between 1995 and 2004, the outcomes of 187 patients with GS 7 PCa (PSA⩽10ng/ml) were analysed from a cohort of 129...
53 CitationsSource